Tatyana B. Postnikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatyana B. Postnikova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Sergeyevich Glotov
Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynaecology, and Reproductology, 199034 St. Petersburg, Russia
4 shared publications - Elena S. Vashukova
Department of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia
4 shared publications - Olga Vladimirovna Pachulia
Department of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia
4 shared publications - Roman A. Illarionov
Department of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia
4 shared publications - Anastasia R. Maltseva
Department of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia
3 shared publications - Olesya Nikolayevna Bespalova
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, 199034 St. Petersburg, Russia
3 shared publications
Latest Publications
- 1 January 2025
- Published by NP Rusmedical Group in Women's Health and Reproduction
- Vol. 69 (4)
Conducting preconception screening among couples planning pregnancy
Aim. To develop guidelines for obstetrician-gynecologists on referring couples who are planning a pregnancy to preconception genetic counseling. Key Points. These guidelines present current understanding of preconception screening, its history, types, inclusion criteria in screening programs, the benefits of this screening, and the challenges associated with its implementation. They also provide recommendations for practicing physicians who may recommend carrier screening to patients. Conclusion. These guidelines are intended for primary care obstetricians and gynecologists working in antenatal clinics and medical centers, as well as general practitioners who see patients planning a pregnancy. Funding source: This study was conducted as part of the research project No. 1022040700843-5-3.2.2 "Development of Methodological Guidelines for Obstetrician-Gynecologists on Referral of Couples Planning Pregnancy for Preconception Medico-Genetic Counseling to Enhance Its Utilization and Effectiveness". Key words: guidelines, preconception screening, pregnancy planning, preconception care, hereditary diseases.
- 1 January 2025
- Published by NP Rusmedical Group in Women's Health and Reproduction
- Vol. 69 (4)
Conducting preconception screening among couples planning pregnancy
Aim. To develop guidelines for obstetrician-gynecologists on referring couples who are planning a pregnancy to preconception genetic counseling. Key Points. These guidelines present current understanding of preconception screening, its history, types, inclusion criteria in screening programs, the benefits of this screening, and the challenges associated with its implementation. They also provide recommendations for practicing physicians who may recommend carrier screening to patients. Conclusion. These guidelines are intended for primary care obstetricians and gynecologists working in antenatal clinics and medical centers, as well as general practitioners who see patients planning a pregnancy. Funding source: This study was conducted as part of the research project No. 1022040700843-5-3.2.2 "Development of Methodological Guidelines for Obstetrician-Gynecologists on Referral of Couples Planning Pregnancy for Preconception Medico-Genetic Counseling to Enhance Its Utilization and Effectiveness". Key words: guidelines, preconception screening, pregnancy planning, preconception care, hereditary diseases.
- Open Access
- 2 December 2024
- Published by MDPI AG in Non-Coding RNA
- Vol. 10 (6) , 61
Urinary miRNA Expression in Pre-Eclampsia During Early and Mid-Pregnancy
Background: Pre-eclampsia (PE) is a serious condition affecting 2–8% of pregnancies worldwide, leading to high maternal and fetal morbidity and mortality. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as potential biomarkers for various pregnancy-related pathologies, including PE. MiRNAs in plasma and serum have been extensively studied, but urinary miRNAs remain underexplored, especially during early pregnancy. This study aimed to investigate the urinary miRNA expression profiles in women with pre-eclampsia during the first and second trimesters. Materials and Methods: A prospective study was conducted using 48 urine samples from 24 pregnant women (n = 12 pre-eclampsia and n = 12 controls). Urine samples were collected in the first (9–13 weeks) and second (22–24 weeks) trimesters. MiRNA isolation, library preparation, and high-throughput sequencing were performed, followed by differential expression and enrichment analyses. Results: In the first trimester, five miRNAs were dysregulated in PE in comparison with the control group (hsa-miR-184, hsa-miR-203a-3p, hsa-miR-205-5p, hsa-miR-223-3p—downregulated; hsa-miR-1-3p—upregulated). In the second trimester, hsa-miR-205-5p and hsa-miR-223-3p were downregulated, and hsa-miR-9-5p, hsa-miR-1-3p, and hsa-miR-206 were upregulated. Conclusions: Our study identified differentially expressed miRNAs in the urine of pre-eclamptic patients during early pregnancy. These findings suggest that specific urinary miRNAs could serve as non-invasive biomarkers for the early detection and risk assessment of pre-eclampsia. The changes in the level of differential expression of miRNAs during gestation highlight their role in the progression of PE. Further research and validation with a larger cohort are needed to explore their clinical potential for improving maternal and fetal outcomes through early intervention.
- 2 December 2024
- Published by MDPI AG in Non-Coding RNA
- Vol. 10 (6) , 61
Open AccessUrinary miRNA Expression in Pre-Eclampsia During Early and Mid-Pregnancy
Background: Pre-eclampsia (PE) is a serious condition affecting 2–8% of pregnancies worldwide, leading to high maternal and fetal morbidity and mortality. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as potential biomarkers for various pregnancy-related pathologies, including PE. MiRNAs in plasma and serum have been extensively studied, but urinary miRNAs remain underexplored, especially during early pregnancy. This study aimed to investigate the urinary miRNA expression profiles in women with pre-eclampsia during the first and second trimesters. Materials and Methods: A prospective study was conducted using 48 urine samples from 24 pregnant women (n = 12 pre-eclampsia and n = 12 controls). Urine samples were collected in the first (9–13 weeks) and second (22–24 weeks) trimesters. MiRNA isolation, library preparation, and high-throughput sequencing were performed, followed by differential expression and enrichment analyses. Results: In the first trimester, five miRNAs were dysregulated in PE in comparison with the control group (hsa-miR-184, hsa-miR-203a-3p, hsa-miR-205-5p, hsa-miR-223-3p—downregulated; hsa-miR-1-3p—upregulated). In the second trimester, hsa-miR-205-5p and hsa-miR-223-3p were downregulated, and hsa-miR-9-5p, hsa-miR-1-3p, and hsa-miR-206 were upregulated. Conclusions: Our study identified differentially expressed miRNAs in the urine of pre-eclamptic patients during early pregnancy. These findings suggest that specific urinary miRNAs could serve as non-invasive biomarkers for the early detection and risk assessment of pre-eclampsia. The changes in the level of differential expression of miRNAs during gestation highlight their role in the progression of PE. Further research and validation with a larger cohort are needed to explore their clinical potential for improving maternal and fetal outcomes through early intervention.
- Open Access
- 6 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11944
Extracellular Vesicles as Biomarkers of Pregnancy Complications
Extracellular vesicles (EVs) are double-membrane vesicles that facilitate intercellular communication and play a pivotal role in both physiological and pathological processes. A substantial body of evidence suggests that EVs play a role in the pathogenesis of various pregnancy complications. Because EVs can be detected in the peripheral blood, they are potential biomarkers for the early diagnosis of pregnancy complications and foetal developmental disorders. The majority of studies have demonstrated a correlation between alterations in the concentration of EVs and changes in their contents and the occurrence of pregnancy complications. Despite the current limitations in establishing a clear link between these findings and the pathogenesis of the disease, as well as the lack of sufficient evidence to support their use in clinical practice, it is noteworthy to highlight the potential role of specific miRNAs carried by EVs in the development of pregnancy complications. These include miR-210 and miR-136-5p for pre-eclampsia and gestational diabetes mellitus, miR-155, miR-26b-5p, miR-181a-5p, miR-495 and miR-374c for pre-eclampsia and preterm birth. The following miRNAs have been identified as potential biomarkers for preterm birth and gestational diabetes mellitus: miR-197-3p and miR-520h, miR-1323, miR-342-3p, miR-132-3p, miR-182-3p, miR-517-3p, miR-222-3p, miR-16-5p and miR-126-3p. Additionally, miR-127-3p has been linked to foetal growth restriction and preterm birth. Nevertheless, it would be premature to propose that EVs can be employed as biomarkers for pregnancy complications. Further research and the accumulation of results obtained using the methods proposed in the MISEV2023 guidelines will enable a definitive conclusion to be reached.
- 6 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11944
Open AccessExtracellular Vesicles as Biomarkers of Pregnancy Complications
Extracellular vesicles (EVs) are double-membrane vesicles that facilitate intercellular communication and play a pivotal role in both physiological and pathological processes. A substantial body of evidence suggests that EVs play a role in the pathogenesis of various pregnancy complications. Because EVs can be detected in the peripheral blood, they are potential biomarkers for the early diagnosis of pregnancy complications and foetal developmental disorders. The majority of studies have demonstrated a correlation between alterations in the concentration of EVs and changes in their contents and the occurrence of pregnancy complications. Despite the current limitations in establishing a clear link between these findings and the pathogenesis of the disease, as well as the lack of sufficient evidence to support their use in clinical practice, it is noteworthy to highlight the potential role of specific miRNAs carried by EVs in the development of pregnancy complications. These include miR-210 and miR-136-5p for pre-eclampsia and gestational diabetes mellitus, miR-155, miR-26b-5p, miR-181a-5p, miR-495 and miR-374c for pre-eclampsia and preterm birth. The following miRNAs have been identified as potential biomarkers for preterm birth and gestational diabetes mellitus: miR-197-3p and miR-520h, miR-1323, miR-342-3p, miR-132-3p, miR-182-3p, miR-517-3p, miR-222-3p, miR-16-5p and miR-126-3p. Additionally, miR-127-3p has been linked to foetal growth restriction and preterm birth. Nevertheless, it would be premature to propose that EVs can be employed as biomarkers for pregnancy complications. Further research and the accumulation of results obtained using the methods proposed in the MISEV2023 guidelines will enable a definitive conclusion to be reached.
- 23 November 2023
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 72 (5) , 15-28
Different risk-assessment models for prediction of preeclampsia and fetal growth restriction in the first trimester in a high-risk pregnancy – which models are better?
BACKGROUND:An increase in the number of pregnant women with various extragenital and gynecological pathologies and motivation for delayed motherhood form a large cohort of patients with a high risk of adverse obstetric outcomes. In this regard, it is necessary to study new approaches that allow stratification of these risks and personalization of pregnancy management and timing of delivery. AIM:The aim of this study was to compare the predictive values of using blood placental growth factor and pregnancy-associated plasma protein-A levels in combined first-trimester screening for the prediction of preeclampsia and fetal growth restriction in a high-risk pregnancy. MATERIALS AND METHODS:This retrospective cohort study enrolled 158 women, who received antenatal care or gave birth on the premises from April 1, 2020 through December 31, 2022. The following comparison groups were defined: pregestational diabetes mellitus (n= 34; group I), chronic arterial hypertension (n= 25; group II); obesity (body mass index more than30 kg/m2;n= 31; group III), older women (40 years and older) with an assisted reproductive technologies pregnancy (n= 8; group IV), and the control group (n= 60; group V). The endpoints of the study were determined as preeclampsia (early and late forms), fetal growth restriction, and the effect of acetylsalicylic acid administration on the risk of placenta-related complications. Various models were used to evaluate the diagnostic value of pregnancy-associated plasma protein-A and placental growth factor in predicting preeclampsia and fetal growth restriction, including maternal characteristics and history, as well as mean arterial pressure, uterine artery pulsatility index, placental growth factor and pregnancy-associated plasma protein-A levels. Statistical data processing was performed using Prism 9 GraphPad (USA). RESULTS:In all high-risk groups, there was a significant decrease in placental growth factor levels compared to the control group (p= 0.032). In patients who have developed preeclampsia, placental growth factor levels were statistically lower. Pregnancy-associated plasma protein-A and placental growth factor have demonstrated the greatest validity for predicting preeclampsia [area under curve 0.88 (0.81–0.94), and 0.93 (0.88–0.99)], early [area under curve 0.88 (0.77–0.95), and0.95 (0.88–0.99)]and late [area under curve 0.86 (0.72–0.9), and 0.91 (0.81–0.97)] forms. Fetal growth restriction prediction was less effective. Administration of acetylsalicylic acid from week 12 to weeks 35–36 of pregnancy contributed to a decrease in the overall risk of developing preeclampsia (relative risk 0.39; 95% confidence interval 0.23–0.65) and fetal growth restriction (in the fetal growth restriction subgroup) (relative risk 0.38; 95% confidence interval 0.12–0.96). CONCLUSIONS:The most effective approach for predicting preeclampsia and fetal growth restriction should include assessment of maternal factors, mean arterial pressure, uterine artery pulsatility index, and placental growth factor. The combined use of pregnancy-associated plasma protein-A and placental growth factor does not significantly improve prognosis.
- 23 November 2023
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 72 (5) , 15-28
Different risk-assessment models for prediction of preeclampsia and fetal growth restriction in the first trimester in a high-risk pregnancy – which models are better?
BACKGROUND:An increase in the number of pregnant women with various extragenital and gynecological pathologies and motivation for delayed motherhood form a large cohort of patients with a high risk of adverse obstetric outcomes. In this regard, it is necessary to study new approaches that allow stratification of these risks and personalization of pregnancy management and timing of delivery. AIM:The aim of this study was to compare the predictive values of using blood placental growth factor and pregnancy-associated plasma protein-A levels in combined first-trimester screening for the prediction of preeclampsia and fetal growth restriction in a high-risk pregnancy. MATERIALS AND METHODS:This retrospective cohort study enrolled 158 women, who received antenatal care or gave birth on the premises from April 1, 2020 through December 31, 2022. The following comparison groups were defined: pregestational diabetes mellitus (n= 34; group I), chronic arterial hypertension (n= 25; group II); obesity (body mass index more than30 kg/m2;n= 31; group III), older women (40 years and older) with an assisted reproductive technologies pregnancy (n= 8; group IV), and the control group (n= 60; group V). The endpoints of the study were determined as preeclampsia (early and late forms), fetal growth restriction, and the effect of acetylsalicylic acid administration on the risk of placenta-related complications. Various models were used to evaluate the diagnostic value of pregnancy-associated plasma protein-A and placental growth factor in predicting preeclampsia and fetal growth restriction, including maternal characteristics and history, as well as mean arterial pressure, uterine artery pulsatility index, placental growth factor and pregnancy-associated plasma protein-A levels. Statistical data processing was performed using Prism 9 GraphPad (USA). RESULTS:In all high-risk groups, there was a significant decrease in placental growth factor levels compared to the control group (p= 0.032). In patients who have developed preeclampsia, placental growth factor levels were statistically lower. Pregnancy-associated plasma protein-A and placental growth factor have demonstrated the greatest validity for predicting preeclampsia [area under curve 0.88 (0.81–0.94), and 0.93 (0.88–0.99)], early [area under curve 0.88 (0.77–0.95), and0.95 (0.88–0.99)]and late [area under curve 0.86 (0.72–0.9), and 0.91 (0.81–0.97)] forms. Fetal growth restriction prediction was less effective. Administration of acetylsalicylic acid from week 12 to weeks 35–36 of pregnancy contributed to a decrease in the overall risk of developing preeclampsia (relative risk 0.39; 95% confidence interval 0.23–0.65) and fetal growth restriction (in the fetal growth restriction subgroup) (relative risk 0.38; 95% confidence interval 0.12–0.96). CONCLUSIONS:The most effective approach for predicting preeclampsia and fetal growth restriction should include assessment of maternal factors, mean arterial pressure, uterine artery pulsatility index, and placental growth factor. The combined use of pregnancy-associated plasma protein-A and placental growth factor does not significantly improve prognosis.
- Open Access
Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy
In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.
Open AccessPlasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy
In recent years evidence has been accumulated showing that miRNAs can act as potential biomarkers or targets for therapy of preterm birth, one of the most important problems in modern obstetrics. We have performed a prospective study of the miRNA profile in the plasma during the first and second trimesters in pregnant women with high risk of preterm birth (n = 13 cases and n = 11 controls). For the study group plasma blood samples at 9–13 weeks before diagnosis and at 22–24 weeks after start of therapy were selected. Using high-throughput sequencing technology we detected differences in the levels of 15 miRNAs (3 upregulated—hsa-miR-122-5p, hsa-miR-34a-5p, hsa-miR-34c-5p; 12 downregulated—hsa-miR-487b-3p, hsa-miR-493-3p, hsa-miR-432-5p, hsa-miR-323b-3p, hsa-miR-369-3p, hsa-miR-134-5p, hsa-miR-431-5p, hsa-miR-485-5p, hsa-miR-382-5p, hsa-miR-369-5p, hsa-miR-485-3p, hsa-miR-127-3p) (log2(FC) ≥ 1.5; FDR ≤ 0.05) during the first trimester compared with the control (non-high-risk of preterm birth pregnant women). All downregulated miRNAs in the first trimester from the placenta-specific C14MC cluster. During the second trimester no differentially expressed miRNAs were found. Our results suggest that the miRNA profile in plasma during early pregnancy may predict a high risk of preterm birth, which is important in preventing gestational problems as early as possible.
- Open Access
High-Throughput Sequencing of Circulating MicroRNAs in Plasma and Serum during Pregnancy Progression
Although circulating microRNAs (miRNAs) in maternal blood may play an important role in regulation of pregnancy progression and serve as non-invasive biomarkers for different gestation complications, little is known about their profile in blood during normally developing pregnancy. In this study we evaluated the miRNA profiles in paired plasma and serum samples from pregnant women without health or gestational abnormalities at three time points using high-throughput sequencing technology. Sequencing revealed that the percentage of miRNA reads in plasma and serum decreased by a third compared to first and second trimesters. We found two miRNAs in plasma (hsa-miR-7853-5p and hsa-miR-200c-3p) and 10 miRNAs in serum (hsa-miR-203a-5p, hsa-miR-495-3p, hsa-miR-4435, hsa-miR-340-5p, hsa-miR-4417, hsa-miR-1266-5p, hsa-miR-4494, hsa-miR-134-3p, hsa-miR-5008-5p, and hsa-miR-6756-5p), that exhibit level changes during pregnancy (p-value adjusted < 0.05). In addition, we observed differences for 36 miRNAs between plasma and serum (p-value adjusted < 0.05), which should be taken into consideration when comparing the results between studies performed using different biosample types. The results were verified by analysis of three miRNAs using qRT-PCR (p < 0.05). The present study confirms that the circulating miRNA profile in blood changes during gestation. Our results set the basis for further investigation of molecular mechanisms, involved in regulation of pregnancy, and the search for biomarkers of gestation abnormalities.
Open AccessHigh-Throughput Sequencing of Circulating MicroRNAs in Plasma and Serum during Pregnancy Progression
Although circulating microRNAs (miRNAs) in maternal blood may play an important role in regulation of pregnancy progression and serve as non-invasive biomarkers for different gestation complications, little is known about their profile in blood during normally developing pregnancy. In this study we evaluated the miRNA profiles in paired plasma and serum samples from pregnant women without health or gestational abnormalities at three time points using high-throughput sequencing technology. Sequencing revealed that the percentage of miRNA reads in plasma and serum decreased by a third compared to first and second trimesters. We found two miRNAs in plasma (hsa-miR-7853-5p and hsa-miR-200c-3p) and 10 miRNAs in serum (hsa-miR-203a-5p, hsa-miR-495-3p, hsa-miR-4435, hsa-miR-340-5p, hsa-miR-4417, hsa-miR-1266-5p, hsa-miR-4494, hsa-miR-134-3p, hsa-miR-5008-5p, and hsa-miR-6756-5p), that exhibit level changes during pregnancy (p-value adjusted < 0.05). In addition, we observed differences for 36 miRNAs between plasma and serum (p-value adjusted < 0.05), which should be taken into consideration when comparing the results between studies performed using different biosample types. The results were verified by analysis of three miRNAs using qRT-PCR (p < 0.05). The present study confirms that the circulating miRNA profile in blood changes during gestation. Our results set the basis for further investigation of molecular mechanisms, involved in regulation of pregnancy, and the search for biomarkers of gestation abnormalities.